Clinical Trial Update: Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating durvalumab with cetuximab in previously treated recurrent or metastatic head and neck squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Head and Neck Cancer
• Head and Neck Neoplasms
• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Cetuximab (cetuximab)
• Durvalumab (durvalumab)

Snippet

Sponsor: Trisha Wise-Draper | Conditions: Recurrent Head and Neck Cancer, Head and Neck Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING